132 related articles for article (PubMed ID: 26709239)
21. Do morphologic characteristics play a role in nodal metastatic progression of well-differentiated pancreatic neuroendocrine tumors?
Ugras N; Hasdemir S; Yerci Ö; Taşar P; Dündar HZ; Macunluoğlu AC
Tumori; 2021 Feb; 107(1):80-85. PubMed ID: 32705937
[TBL] [Abstract][Full Text] [Related]
22. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.
Bahra M; Jacob D; Pascher A; Plockinger U; Kristiansen G; Neuhaus P; Langrehr JM
J Gastroenterol Hepatol; 2007 Jun; 22(6):930-5. PubMed ID: 17489964
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
25. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
27. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors.
Chi Y; Du F; Zhao H; Wang JW; Cai JQ
World J Gastroenterol; 2014 Nov; 20(43):16252-7. PubMed ID: 25473180
[TBL] [Abstract][Full Text] [Related]
29. Heme oxygenase-1 promoter polymorphism is a predictor of disease relapse in pancreatic neuroendocrine tumors.
Vashist YK; Uzunoglu G; Deutsch L; Kalinin V; Zehler O; Alzadjali A; Kutup A; Izbicki JR; Yekebas EF
J Surg Res; 2011 Apr; 166(2):e121-7. PubMed ID: 21236443
[TBL] [Abstract][Full Text] [Related]
30. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
31. Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.
Nanno Y; Toyama H; Zen Y; Akita M; Ando Y; Mizumoto T; Ueda Y; Ajiki T; Okano K; Suzuki Y; Fukumoto T
Ann Surg Oncol; 2018 Oct; 25(11):3358-3364. PubMed ID: 30054822
[TBL] [Abstract][Full Text] [Related]
32. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
33. [Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
Soriano-Izquierdo A; Adet AC; Gallego R; Miquel R; Castells A; Pellisé M; Nadal C; López-Boado MA; Piqué JM; Gascón P; Conill C; Bombí A; Fernández-Cruz L; Maurel J; Navarro S
Med Clin (Barc); 2009 Feb; 132(5):163-71. PubMed ID: 19211081
[TBL] [Abstract][Full Text] [Related]
34. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
35. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
37. Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study.
Zou S; Jiang Y; Wang W; Zhan Q; Deng X; Shen B
Int J Surg; 2020 Feb; 74():86-91. PubMed ID: 31926324
[TBL] [Abstract][Full Text] [Related]
38. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment.
Chung JC; Choi DW; Jo SH; Heo JS; Choi SH; Kim YI
World J Surg; 2007 Mar; 31(3):579-85. PubMed ID: 17219270
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
[TBL] [Abstract][Full Text] [Related]
40. Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection.
Arai T; Kobayashi A; Fujinaga Y; Yokoyama T; Shimizu A; Motoyama H; Kitagawa N; Notake T; Shirota T; Fukushima K; Masuo H; Kadoya M; Miyagawa S
Pancreatology; 2016; 16(3):397-402. PubMed ID: 26850565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
